Genetic and Molecular Lab Testing Audits: Medical Necessity and Ordering Physician Documentation

Why genetic and molecular laboratory tests are a top Medicare audit and enforcement target, what OIG found about spending and oversight, how MolDX and coverage policies apply, and what ordering physician documentation labs and practices need to defend medical necessity.

KNOWLEDGE CENTER

11/15/202612 min read

Genetic and molecular testing has transformed medicine, enabling targeted cancer therapy, diagnosis of rare diseases, and guidance on drug selection. It has also become one of the largest and fastest-growing areas of Medicare laboratory spending, and one of the most heavily scrutinized. According to OIG's January 2026 annual report on Medicare Part B laboratory spending, genetic tests made up about 5 percent of lab test volume but 43 percent of Part B lab spending in 2024, and spending on genetic testing rose 20 percent from 2023 to 2024. Medicare paid an average of $794 per enrollee for genetic testing in 2024, compared with just over $200 for non-genetic testing.

At the same time, genetic testing has been a recurring focus of fraud enforcement. DOJ's 2025 National Health Care Fraud Takedown charged 49 defendants in connection with more than $1.17 billion in alleged fraudulent claims involving telemedicine and genetic testing, and the 2026 takedown again highlighted genetic testing schemes, including defendants wanted in schemes of $547 million and $90 million. OIG has issued audits finding weaknesses in CMS oversight of high-priced molecular tests and announced new 2026 to 2028 audits of genetic testing.

This article explains the coverage framework for genetic and molecular tests, what auditors look for, the ordering physician documentation that supports medical necessity, and how labs and practices can reduce risk. It is educational and not legal advice. Coverage rules vary by MAC and test, so labs and practices should confirm current requirements and consult experienced healthcare counsel.

The Coverage Framework

Medicare's Basic Rules for Diagnostic Tests

Under 42 CFR 410.32(a), diagnostic laboratory tests must be ordered by the physician or qualified nonphysician practitioner who is treating the beneficiary, that is, the practitioner who furnishes a consultation or treats the beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Tests not ordered by the treating practitioner are not reasonable and necessary. The ordering practitioner must maintain documentation of medical necessity in the beneficiary's medical record, and the laboratory must maintain the order and other documentation it receives.

Screening Versus Diagnostic Testing

Medicare generally does not cover screening tests unless a statute specifically authorizes them. Many genetic tests marketed for risk assessment in patients without signs or symptoms are considered screening and are not covered. Hereditary cancer testing, for example, is generally covered only for beneficiaries who have a personal history of a relevant cancer or meet specific criteria, and pharmacogenomic testing is generally covered only when the results will guide decisions about a specific drug the patient is taking or is expected to take.

National Coverage Determinations

Some genetic tests are governed by National Coverage Determinations, such as the NCD for next generation sequencing for patients with advanced cancer, which addresses coverage of FDA-approved companion diagnostics and certain other tests, and coverage of germline testing in specific circumstances.

Local Coverage Determinations and MolDX

Many molecular tests are governed by Local Coverage Determinations. The Molecular Diagnostic Services Program (MolDX), administered by Palmetto GBA, sets coverage policies for molecular diagnostic tests in 28 states through participating MACs. MolDX requires labs to register tests and obtain a unique identifier, known as a Z-code, and to submit technical assessments demonstrating analytical and clinical validity and clinical utility for coverage. Outside MolDX jurisdictions, MACs apply their own LCDs and billing articles. CMS has sought comment on expanding MolDX-like oversight more broadly as part of its fraud-fighting initiatives.

Coding

Molecular pathology tests are billed using Tier 1 and Tier 2 molecular pathology CPT codes, genomic sequencing procedure codes, multianalyte assays with algorithmic analyses codes, Proprietary Laboratory Analyses codes, and unlisted codes. Tier 2 codes and unlisted codes cover groups of less common tests and have been vulnerable to miscoding. Accurate coding that reflects the test actually performed is essential.

What OIG Has Found

Rising Spending

OIG's January 2026 report found that Medicare Part B lab spending rose to $8.4 billion in 2024, with genetic testing driving most of the increase while spending on non-genetic testing declined. The report identified high-spending codes, including an infectious disease code used when no organism-specific code exists, which accounted for $442.5 million in 2024, a 51 percent increase from 2023. OIG's annual reports are widely viewed as a roadmap for future audits and investigations.

Oversight of High-Priced Tests

In a 2023 audit, OIG found that CMS's oversight of Medicare payments for CPT code 81408, the highest-paid molecular pathology test at the time, was not adequate to reduce the risk of up to $888 million in improper payments. OIG found that CMS and the MACs did not ensure that enrollees had established relationships with ordering providers, did not ensure that payments were related to diseases associated with genes that would generally be tested under that code, and did not adequately monitor the number of tests billed.

New Audits

In June 2026, OIG announced a work plan project examining trends and vulnerabilities in genetic tests covered under Part B, including whether geographic variations exist between jurisdictions that do and do not participate in MolDX, and a separate project on Medicare payments for expanded laboratory panels testing six or more pathogens. Both projects are expected to run from 2026 to 2028.

Fraud Alerts

OIG has issued special fraud alerts warning about schemes in which telemarketers, telemedicine companies, and labs collaborate to obtain orders for genetic tests from practitioners who have no relationship with the patient and do not use the results. These alerts describe red flags such as practitioners ordering tests after brief or no interactions with patients, labs paying telemedicine companies or marketers per test, and patients being solicited through telemarketing or health fairs.

What Auditors Look For

A Valid Order From the Treating Practitioner

Auditors verify that a written or electronic order exists, that it was signed by a practitioner who was treating the beneficiary, and that the practitioner used or intended to use the results in the beneficiary's care. Orders from practitioners with no prior or subsequent relationship with the patient are a major red flag, as OIG's 81408 audit highlighted.

Medical Necessity in the Ordering Practitioner's Record

The most important documentation is in the ordering practitioner's medical record, not the lab's. Auditors look for:

• The patient's relevant signs, symptoms, diagnosis, or personal and family history.

• The clinical question the test is intended to answer.

• How the test results will affect management, such as treatment selection, drug dosing, surveillance, or further testing.

• Satisfaction of coverage criteria in the applicable NCD, LCD, or billing article.

• Any genetic counseling, where required or appropriate.

Coverage Criteria

Auditors compare documentation with specific coverage criteria. For hereditary cancer testing, criteria often involve personal history of specific cancers, age at diagnosis, and family history. For pharmacogenomic testing, criteria involve a specific drug with known gene-drug interactions. For tumor sequencing, criteria involve cancer type, stage, and treatment plans.

Test Registration and Coding

In MolDX jurisdictions, auditors check that the test was registered, that the correct Z-code was submitted, and that the test met coverage requirements. Everywhere, auditors check that the CPT code matches the test performed and that unlisted or Tier 2 codes were used appropriately.

Frequency and Duplication

Auditors look for repeat germline tests, which generally should not be repeated, and for overlapping panels billed for the same patient.

Use of Results

Auditors may ask whether results were reported to and used by the ordering practitioner. Results that were never reviewed or acted on can suggest that the test was not reasonable and necessary.

Responsibilities of Labs and Ordering Practitioners

Labs

Labs submit the claims and receive payment, so they bear significant risk. Labs should:

• Obtain complete, signed orders before performing tests.

• Verify that ordering practitioners have a treating relationship with patients.

• Request medical necessity documentation from ordering practitioners when needed, particularly for high-cost tests.

• Register tests and obtain Z-codes in MolDX jurisdictions.

• Code tests accurately.

• Monitor ordering patterns for red flags.

• Avoid financial arrangements with referral sources, marketers, and telemedicine companies that could violate the Anti-Kickback Statute or the Eliminating Kickbacks in Recovery Act where applicable.

Ordering Practitioners

Ordering practitioners also face risk, including False Claims Act liability and exclusion, when they sign orders for tests that are not medically necessary. Practitioners should:

• Order tests only for patients they are treating, after an appropriate evaluation.

• Document the clinical basis and how results will be used.

• Review and act on results.

• Decline to sign orders presented by marketers, telemedicine companies, or labs for patients they have not evaluated.

• Be wary of compensation for telemedicine consultations tied to test orders.

Common Audit Findings

• Orders signed by practitioners with no treating relationship.

• Missing or incomplete orders.

• Medical records that do not document signs, symptoms, history, or how results will be used.

• Tests that are screening rather than diagnostic.

• Repeat germline testing.

• Large panels billed when a narrower test would answer the clinical question.

• Miscoding, including misuse of Tier 2 and unlisted codes.

• Missing Z-codes or unregistered tests in MolDX jurisdictions.

Responding to a Genetic Testing Audit

• Respond to every documentation request by the deadline.

• Obtain records from the ordering practitioner that document the clinical rationale, not just the order.

• Include the requisition, the order, the test report, evidence of delivery to the ordering practitioner, and coverage-related documentation.

• Review findings against the applicable NCD, LCD, and billing article.

• Challenge sampling and extrapolation where used.

• Appeal through the Medicare appeals process.

• Engage counsel immediately if the audit involves UPICs, subpoenas, or suggestions of kickbacks or telemedicine schemes.

Building a Compliance Program for Genetic Testing

• Maintain a test menu with coverage criteria and documentation requirements for each test.

• Use requisition forms that capture clinical information relevant to coverage, without pre-checked diagnoses or leading language.

• Implement intake review for high-cost tests to confirm order completeness and coverage criteria before testing.

• Verify ordering practitioners' treating relationships and monitor for unusual ordering patterns.

• Review marketing practices and all financial relationships with counsel.

• Train sales staff on compliance.

• Audit claims regularly.

• Report and return identified overpayments within 60 days.

Common Mistakes

• Relying on the requisition form alone to support medical necessity.

• Accepting orders from telemedicine practitioners with no ongoing relationship.

• Using requisitions with pre-printed diagnosis codes.

• Billing Tier 2 or unlisted codes without confirming they fit the test.

• Paying marketers or referral sources based on volume.

• Failing to register tests in MolDX jurisdictions.

Test-Specific Documentation Considerations

Coverage requirements and audit focus differ by category of test. The following overview highlights the documentation reviewers commonly expect for several major categories, though the applicable NCD, LCD, or billing article always controls.

Hereditary Cancer Testing

Germline testing for hereditary cancer syndromes generally requires that the beneficiary have a personal history of a cancer associated with the syndrome being tested, and often that specific criteria related to age at diagnosis, tumor characteristics, or family history be met. The ordering practitioner's record should document the patient's cancer diagnosis, relevant pathology, family history in sufficient detail to apply criteria, and how results will affect treatment, surveillance, or risk-reducing interventions. Testing of an unaffected patient based only on family history is commonly treated as screening.

Pharmacogenomic Testing

Pharmacogenomic tests are generally covered when the patient is being considered for, or is taking, a drug with a known gene-drug interaction that affects safety or efficacy, and when results will guide prescribing. The record should identify the drug, the clinical decision at stake, and how the result will be used. Broad pharmacogenomic panels ordered without a specific medication decision are frequent audit targets.

Tumor Profiling and Next Generation Sequencing

Somatic testing of tumors for patients with cancer is generally tied to cancer type, stage, and treatment decisions. The record should document the diagnosis and stage, prior treatment, and how results will inform therapy selection or clinical trial eligibility. Repeat testing should be justified by a change in clinical circumstances, such as disease progression.

Infectious Disease Molecular Panels

Multiplex panels that test for many pathogens at once have grown rapidly and are now the subject of an OIG work plan project. Reviewers examine whether the patient's symptoms justified a broad panel rather than a targeted test, and whether the number of pathogens tested matched clinical need. Documentation should describe the patient's presentation, the suspected infections, and why a panel of the size ordered was appropriate.

Cardiovascular, Neurologic, and Other Germline Testing

Testing for inherited cardiac, neurologic, and other conditions generally requires signs, symptoms, or diagnostic findings suggestive of the condition, or a known familial variant. The record should document the findings that prompted testing and how results will change management.

The Laboratory's Role in Obtaining Documentation

Medicare places the duty to document medical necessity primarily on the ordering practitioner, but the laboratory submits the claim and bears the financial consequence when documentation is missing. Labs therefore need processes for obtaining supporting documentation, particularly for high-cost tests.

Effective practices include requesting relevant clinical notes at the time of order for tests above a defined cost threshold, using requisitions that ask for the clinical indication and relevant history in the practitioner's own words, and following up with the ordering practitioner when an order lacks key information. Labs should also have a process for retrieving records quickly when a contractor sends a documentation request, since the lab may need the ordering practitioner's cooperation to respond on time. Agreements or communications with frequent ordering practices can set expectations for prompt record sharing in response to audits, without creating any inducement to order tests.

Labs should not alter, add to, or create clinical documentation, and they should not ask practitioners to sign attestations that do not reflect what occurred. If documentation does not support a test, the appropriate response is to address the claim, not to manufacture support.

Telehealth Ordering and Remote Patient Relationships

Telehealth is a legitimate way to deliver care, and Medicare does not prohibit genetic tests ordered through telehealth encounters. The concern is with arrangements in which the telehealth encounter exists only to generate a test order. OIG's special fraud alert on telehealth companies describes characteristics of suspect arrangements, including practitioners who are paid per order or per consultation tied to orders, who have limited interaction with patients, who receive patient information gathered by marketers, and who are expected to order a predetermined set of tests.

When a test is ordered after a telehealth encounter, both labs and practitioners should be prepared to show that a genuine treating relationship existed, that the practitioner evaluated the patient, and that the practitioner received and used the results. Labs that receive a large share of orders from telehealth practitioners who do not otherwise treat the patient should evaluate those referral sources carefully.

Overpayments and Self-Disclosure

When a lab or practice identifies claims that were not supported, the 60-day overpayment rule may require quantification and repayment. CMS revised its overpayment regulations, effective January 1, 2025, to allow up to 180 days for a timely, good-faith investigation before the 60-day period begins, and labs should work with counsel to apply these rules correctly. Where conduct may involve potential fraud, such as kickbacks or knowing submission of claims for unnecessary tests, counsel may evaluate the OIG Self-Disclosure Protocol. Prompt, well-documented corrective action and repayment generally place an organization in a better position than waiting for an external audit.

Myths About Genetic Testing Audits

Myth: The Lab Is Protected if It Has a Signed Order

Medical necessity must be supported by the ordering practitioner's record, and labs can be liable for claims for unnecessary tests.

Myth: Family History Alone Justifies Testing

Medicare generally does not cover screening tests, and coverage criteria often require personal history or specific clinical circumstances.

Myth: Telemedicine Orders Are Always Valid

Orders from practitioners who do not treat the patient or use the results do not meet Medicare requirements, and OIG has warned about telemedicine schemes.

Myth: Only Fraudulent Labs Are Audited

OIG's spending reports and new audits target high-spending codes and patterns, and legitimate labs with documentation gaps can face large overpayment demands.

Questions Leadership Should Ask

• Do we verify a treating relationship for every ordering practitioner?

• Do we obtain medical necessity documentation for high-cost tests?

• Are our requisition forms compliant?

• Are our tests registered and coded correctly, including Z-codes?

• Do any marketing or financial relationships raise kickback concerns?

• Are we prepared for OIG's 2026 to 2028 genetic testing audits?

Key Takeaways

• Genetic tests drove 43 percent of Medicare Part B lab spending in 2024 despite making up about 5 percent of volume, and OIG has launched new audits for 2026 to 2028.

• Tests must be ordered by the treating practitioner who uses the results, and medical necessity must be documented in the practitioner's record.

• Coverage depends on NCDs, LCDs, and, in 28 states, MolDX registration and technical assessment.

• OIG found inadequate oversight of high-priced molecular tests, and DOJ continues to prosecute telemedicine and genetic testing schemes.

• Labs and ordering practitioners share responsibility, and complete orders, clinical documentation, accurate coding, and compliant financial relationships are essential.

How HealthBridge Can Help

HealthBridge helps clinical laboratories and ordering practices reduce genetic and molecular testing audit risk. Our team can map coverage criteria and documentation requirements for your test menu, review requisition forms and intake processes, audit claims for order, medical necessity, and coding compliance, and help prepare responses and appeals. We also help organizations monitor ordering patterns and support counsel in reviewing marketing and financial relationships. If your organization performs or orders genetic tests, please get in touch with us. We will be happy to help you with this topic.

References

• HHS Office of Inspector General. Medicare Part B Spending on Lab Tests annual data report (January 2026). https://oig.hhs.gov/reports/all/

• HHS Office of Inspector General. CMS's Oversight of Medicare Payments for the Highest Paid Molecular Pathology Genetic Test Was Not Adequate To Reduce the Risk of up to $888 Million in Improper Payments (A-09-22-03010, 2023). https://oig.hhs.gov/reports/all/2023/cmss-oversight-of-medicare-payments-for-the-highest-paid-molecular-pathology-genetic-test-was-not-adequate-to-reduce-the-risk-of-up-to-888-million-in-improper-payments/

• HHS Office of Inspector General. Work Plan: Trends and Vulnerabilities in Genetic Tests Covered Under Medicare Part B (announced June 15, 2026). https://oig.hhs.gov/reports/work-plan/browse-work-plan-projects/trends-and-vulnerabilities-in-genetic-tests-covered-under-medicare-part-b/

• HHS Office of Inspector General. Work Plan: Medicare Payments to Providers for Selected Expanded Laboratory Panels. https://oig.hhs.gov/reports/work-plan/browse-work-plan-projects/medicare-payments-to-providers-for-selected-expanded-laboratory-panels/

• HHS Office of Inspector General. Special Fraud Alert: OIG Alerts Practitioners to Exercise Caution When Entering Into Arrangements With Purported Telehealth and Telemedicine Companies (July 2022). https://oig.hhs.gov/documents/root/1045/sfa-telefraud.pdf

• HHS Office of Inspector General. Fraud Alert: Genetic Testing Scam. https://oig.hhs.gov/fraud/consumer-alerts/fraud-alert-genetic-testing-scam/

• U.S. Department of Justice. National Health Care Fraud Takedown (June 23, 2026). https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-2026

• U.S. Department of Justice. 2025 National Health Care Fraud Takedown (June 30, 2025). https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-2025

• Centers for Medicare & Medicaid Services. National Coverage Determination 90.2, Next Generation Sequencing. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372

• Centers for Medicare & Medicaid Services. Medicare Coverage Database (LCDs and billing articles, including MolDX policies). https://www.cms.gov/medicare-coverage-database/search.aspx

• Electronic Code of Federal Regulations. 42 CFR 410.32, Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.32

• U.S. Code. 42 U.S.C. 1395y(a)(1)(A), Reasonable and necessary exclusion. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395y

• U.S. Code. 42 U.S.C. 1320a-7b(b), Anti-Kickback Statute; and 18 U.S.C. 220, Eliminating Kickbacks in Recovery Act. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section220

• Electronic Code of Federal Regulations. 42 CFR 401.305, Requirements for reporting and returning of overpayments. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-A/part-401/subpart-D/section-401.305

• U.S. Code. 42 U.S.C. 1320a-7k(d), Reporting and returning of overpayments. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320a-7k

Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources